- Home
- DSGN vs MPV Comparison
DSGN vs MPV Comparison
Compare DSGN & MPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- MPV
- Stock Information
- Founded
- DSGN 2017
- MPV 1988
- Country
- DSGN United States
- MPV United States
- Employees
- DSGN N/A
- MPV N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- MPV Finance Companies
- Sector
- DSGN Health Care
- MPV Finance
- Exchange
- DSGN Nasdaq
- MPV Nasdaq
- Market Cap
- DSGN 208.9M
- MPV 201.1M
- IPO Year
- DSGN 2021
- MPV N/A
- Fundamental
- Price
- DSGN $6.54
- MPV $20.20
- Analyst Decision
- DSGN
- MPV
- Analyst Count
- DSGN 0
- MPV 0
- Target Price
- DSGN N/A
- MPV N/A
- AVG Volume (30 Days)
- DSGN 173.8K
- MPV 25.2K
- Earning Date
- DSGN 11-06-2025
- MPV 01-01-0001
- Dividend Yield
- DSGN N/A
- MPV 8.71%
- EPS Growth
- DSGN N/A
- MPV N/A
- EPS
- DSGN N/A
- MPV 1.71
- Revenue
- DSGN N/A
- MPV N/A
- Revenue This Year
- DSGN N/A
- MPV N/A
- Revenue Next Year
- DSGN N/A
- MPV N/A
- P/E Ratio
- DSGN N/A
- MPV $9.35
- Revenue Growth
- DSGN N/A
- MPV N/A
- 52 Week Low
- DSGN $2.60
- MPV $11.18
- 52 Week High
- DSGN $7.77
- MPV $16.42
- Technical
- Relative Strength Index (RSI)
- DSGN 54.51
- MPV 59.07
- Support Level
- DSGN $5.88
- MPV $19.40
- Resistance Level
- DSGN $7.59
- MPV $20.56
- Average True Range (ATR)
- DSGN 0.51
- MPV 0.42
- MACD
- DSGN -0.06
- MPV 0.03
- Stochastic Oscillator
- DSGN 37.42
- MPV 88.32
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.